Publications by authors named "Quinn Casuccio Treen"
Psychosis spectrum disorders (PSDs), as well as other severe mental illnesses where psychotic features may be present, like bipolar disorder, are associated with intrinsic metabolic abnormalities. Antipsychotics (APs), the cornerstone of treatment for PSDs, incur additional metabolic adversities including weight gain. Currently, major gaps exist in understanding psychosis illness biomarkers, as well as risk factors and mechanisms for AP-induced weight gain.
View Article and Find Full Text PDFArticle Synopsis
- Patients with schizophrenia experience high rates of metabolic issues, leading to a significant loss of life due to cardiovascular diseases, prompting research into potential treatments.
- In a study of 30 overweight or obese individuals under 40 with schizophrenia and prediabetes/type 2 diabetes, participants were given either metformin or a placebo for 4 months to assess glucose and insulin improvements.
- Results showed that metformin significantly lowered insulin resistance and fasting blood glucose compared to placebo, indicating its effectiveness in managing dysglycemia and insulin sensitivity in this high-risk population, despite no major differences in other health measures.